• Extensive PK studies and clinical trials have been completed by prior sponsor, NASA, in collaboration with Nastech and the US Navy. A New Drug Application (NDA) on a 505(b)2 pathway is being developed for submission to the FDA.

​​

INSCOP

• Two well-controlled parallel, double-blind phase III trials completed showing efficacy and safety

• Over 1,000 patients have been dosed, with virtually no SAEs

• Fast Track designation has been granted by the FDA

• Work remains on CMC (i.g., stability batches)

               Summary of Intranasal Scopolamine Hydrobromide Gel Studies